【作者】 周素芳； 罗国容； 蓝玲；

【Author】 Zhou Sufang , Luo Guorong, Lan ling (Guangxi medical university, Nanning 530021)

【机构】 广西医科大学基础医学院；

【摘要】 目的:用基因工程的方法构建、表达和纯化肝癌肿瘤抗原蛋白SMP-30,检测肝癌、肝硬化及其它肿瘤病人血清中相应抗体的阳性率。方法:PCR方法扩增经SEREX技术筛选出的人肝细胞癌抗原SMP-30羧基末端165个AA的DNA序列,构建其表达质粒,经原核表达和亲和层析纯化获得目的蛋白。采用ELISA方法检测肝癌、肝硬化与其它肿瘤患者血清中抗SMP-30抗体的阳性率。结果:目的蛋白经N-末端氨基酸序列测序证实为SMP-30蛋白。以57例正常人血清为对照,肝癌、慢性肝炎、肝硬化和鼻咽癌血清中SMP-30抗体阳性率分别为39.4%(13/33)、15.0%(3/20)、66.7%(8/12)和21.6%(5/23)。7例肺癌和25例胃肠疾病中无一例阳性。结论:SMP-30蛋白可望作为肝癌肿瘤和肝病的血清学诊断工具。更多还原

【Abstract】 Objective: to obtain and purify hepatocellular carcinoma antigen SMP30 for study of its immunology. Methods: the cDNA that represents C-end 165 amino acids of SMP-30 was amplified and then recorabined in expressing plasmid. The SMP-30 fusion protein was expressed in E. Coli. The protein was characterized by analysis of amino acids sequence. Sera from 120 patients and 57 normal individuals were tested for antibody to SMP-30 in ELISA using recombinant SMP-30 protein. Result. the N-end 15 amino acids of SMP30 were correct by sequence analysis. ELISA results showed that 13/33 of hepatocellular carcinoma, 3/20 of chronic hepatitis, 8/12 of hepatocirrhosis and 5/23 of nasopharynx cancer patients had antibody against SMP30. No SMP30 antibody was detected in the sera of 7 lung cancers, 25 gastric-intestine patients and 57 normal individuals. Conclusion: SMP-30 protein can be used for liver tumor antigen and liver diseases seroreactivity seroscreening.更多还原